Mylan NV (NASDAQ:MYL)

38.63
Delayed Data
As of Jun 21
 -0.24 / -0.62%
Today’s Change
29.39
Today|||52-Week Range
47.82
-8.70%
Year-to-Date
Amgen's Neulasta Has a New Competitor
Jun 17 / GuruFocus News - Paid Partner Content
Mylan (MYL) to Get CRL Again for Generic Advair from FDA
Jun 14 / Zacks.com - Paid Partner Content
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
Jun 15 / Zacks.com - Paid Partner Content
Mylan (MYL) Up 10.2% Since Earnings Report: Can It Continue?
Jun 08 / Zacks.com - Paid Partner Content
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
Jun 15 / Zacks.com - Paid Partner Content
Mylan CEO: You can't build a company in a quarter
Jun 04 / CNNMoney.com
Company News For Jun 15, 2018
Jun 15 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close38.87
Today’s open38.93
Day’s range38.33 - 39.02
Volume2,094,562
Average volume (3 months)4,642,055
Market cap$19.7B
Data as of 4:00pm ET, 06/21/2018

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)+17.63%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+7.06%
P/E ratio28.6
Price/Sales1.91
Price/Book1.51

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.09+0.09%
PRGOPerrigo Company PLC-0.51-0.67%
JAZZJazz Pharmaceuticals...-3.05-1.67%
ALNYAlnylam Pharmaceutic...-2.57-2.44%
Data as of 4:02pm ET, 06/21/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)$1.24
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts